

Michael R Grunwald

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/194954/publications.pdf>

Version: 2024-02-01

67
papers

1,734
citations

361413

20
h-index

302126

39
g-index

70
all docs

70
docs citations

70
times ranked

2502
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 1 | The mutational landscape in chronic myelomonocytic leukemia and its impact on allogeneic hematopoietic cell transplantation outcomes: a Center for Blood and Marrow Transplantation Research (CIBMTR) analysis. <i>Haematologica</i> , 2023, 108, 150-160. | 3.5 | 10 |
| 2 | Hemorrhage in patients with polycythemia vera receiving aspirin with an anticoagulant: a prospective, observational study. <i>Haematologica</i> , 2022, 107, 1106-1110. | 3.5 | 8 |
| 3 | Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and <i>t(8;21) KMT2A</i> -rearranged AML. <i>Blood Advances</i> , 2022, 6, 828-847. | 5.2 | 5 |
| 4 | Haploidentical vs sibling, unrelated, or cord blood hematopoietic cell transplantation for acute lymphoblastic leukemia. <i>Blood Advances</i> , 2022, 6, 339-357. | 5.2 | 35 |
| 5 | Allogeneic blood or marrow transplantation with haploidentical donor and post-transplantation cyclophosphamide in patients with myelofibrosis: a multicenter study. <i>Leukemia</i> , 2022, 36, 856-864. | 7.2 | 26 |
| 6 | HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamide. <i>Blood</i> , 2022, 139, 1452-1468. | 1.4 | 52 |
| 7 | Umbilical Cord Blood or HLA-Haploidentical Transplantation: Real-World Outcomes versus Randomized Trial Outcomes. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 109.e1-109.e8. | 1.2 | 12 |
| 8 | Relapse and Disease-Free Survival in Patients With Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation Using Older Matched Sibling Donors vs Younger Matched Unrelated Donors. <i>JAMA Oncology</i> , 2022, 8, 404. | 7.1 | 32 |
| 9 | Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 187.e1-187.e10. | 1.2 | 3 |
| 10 | Optimization of physician and specialty pharmacy clinical workflow in assessment of risk category and symptom burden in patients with myelofibrosis (MF). <i>Leukemia and Lymphoma</i> , 2022, , 1-3. | 1.3 | 0 |
| 11 | Financial Toxicity Intervention Improves Outcomes in Patients With Hematologic Malignancy. <i>JCO Oncology Practice</i> , 2022, 18, e1494-e1504. | 2.9 | 16 |
| 12 | Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myelogenous Leukemia and Myelodysplastic Syndromes with Low/Intermediate but not High Disease Risk Index: A Center for International Blood and Marrow Transplant Research Study. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 68.e1-68.e9. | 1.2 | 15 |
| 13 | Comanagement Strategy Between Academic Institutions and Community Practices to Reduce Induction Mortality in Acute Promyelocytic Leukemia. <i>JCO Oncology Practice</i> , 2021, 17, e497-e505. | 2.9 | 14 |
| 14 | Hematopoietic Cell Transplantation in the Treatment of Newly Diagnosed Adult Acute Myeloid Leukemia: An Evidence-Based Review from the American Society of Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 6-20. | 1.2 | 45 |
| 15 | Alternative donor transplantation for myelodysplastic syndromes: haploidentical relative and matched unrelated donors. <i>Blood Advances</i> , 2021, 5, 975-983. | 5.2 | 27 |
| 16 | Impact of depth of clinical response on outcomes of acute myeloid leukemia patients in first complete remission who undergo allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 2108-2117. | 2.4 | 6 |
| 17 | HLA Haploidentical versus Matched Unrelated Donor Transplants with Post-Transplant Cyclophosphamide based prophylaxis. <i>Blood</i> , 2021, 138, 273-282. | 1.4 | 88 |
| 18 | Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease: a real-world outcomes analysis. <i>British Journal of Haematology</i> , 2021, 195, 429-432. | 2.5 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 19 | Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 921.e1-921.e10. | 1.2 | 11 |
| 20 | Allogeneic Transplantation to Treat Therapy-Related Myelodysplastic Syndrome and Acute Myelogenous Leukemia in Adults. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 923.e1-923.e12. | 1.2 | 15 |
| 21 | An adapted European LeukemiaNet genetic risk stratification for acute myeloid leukemia patients undergoing allogeneic hematopoietic cell transplant. A CIBMTR analysis. <i>Bone Marrow Transplantation</i> , 2021, 56, 3068-3077. | 2.4 | 13 |
| 22 | Planned Granulocyte Colony-Stimulating Factor Adversely Impacts Survival after Allogeneic Hematopoietic Cell Transplantation Performed with Thymoglobulin for Myeloid Malignancy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 993.e1-993.e8. | 1.2 | 4 |
| 23 | Incidence and Risk Factors Associated with Fatal Graft Vs Host Disease after Solid Organ Transplantation in United Network of Organ Transplant Database. <i>Blood</i> , 2021, 138, 4067-4067. | 1.4 | 0 |
| 24 | Acute Myeloid Leukemia Patients in Complete Remission with Positive Measurable Residual Disease Prior to Allogeneic Transplant Have Worse Outcomes, Similar to Active Disease Regardless of Conditioning Regimen Intensity and Post-Transplant Cyclophosphamide Administration. <i>Blood</i> , 2021, 138, 4907-4907. | 1.4 | 0 |
| 25 | A Real-World Evaluation of the Association between Elevated Blood Counts and Thrombotic Events in Polycythemia Vera (Analysis of Data from the REVEAL Study). <i>Blood</i> , 2021, 138, 239-239. | 1.4 | 4 |
| 26 | Treatment Patterns and Blood Counts in Patients With Polycythemia Vera Treated With Hydroxyurea in the United States: An Analysis From the REVEAL Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 219-225. | 0.4 | 13 |
| 27 | Evaluation of <i>CYP2C19</i> Genotype-Guided Voriconazole Prophylaxis After Allogeneic Hematopoietic Cell Transplant. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 571-579. | 4.7 | 27 |
| 28 | Timing of allogeneic hematopoietic cell transplantation (alloHCT) for chronic myeloid leukemia (CML) patients. <i>Leukemia and Lymphoma</i> , 2020, 61, 2811-2820. | 1.3 | 7 |
| 29 | Reduced intensity conditioning for acute myeloid leukemia using melphalan- vs busulfan-based regimens: a CIBMTR report. <i>Blood Advances</i> , 2020, 4, 3180-3190. | 5.2 | 18 |
| 30 | A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2139-2146. | 2.0 | 14 |
| 31 | Survival following allogeneic transplant in patients with myelofibrosis. <i>Blood Advances</i> , 2020, 4, 1965-1973. | 5.2 | 63 |
| 32 | Impact of cytogenetic abnormalities on outcomes of adult Philadelphia-negative acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation: a study by the Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research. <i>Haematologica</i> , 2020, 105, 1329-1338. | 3.5 | 23 |
| 33 | Clinical Benefit of Crenolanib, with or without Salvage Chemotherapy, in Multiply Relapsed, FLT3 Mutant AML Patients after Prior Treatment with Gilteritinib. <i>Blood</i> , 2020, 136, 8-9. | 1.4 | 4 |
| 34 | Financial Toxicity Intervention Improves Quality of Life in Hematologic Malignancy Patients. <i>Blood</i> , 2020, 136, 21-21. | 1.4 | 1 |
| 35 | Clinical Characteristics and Treatment Patterns By Risk Stratification in Patients with Essential Thrombocythemia: An Analysis of the MOST Study. <i>Blood</i> , 2020, 136, 12-13. | 1.4 | 0 |
| 36 | Financial Toxicity Intervention Decreases Mortality in High Risk Hematologic Malignancy Patients. <i>Blood</i> , 2020, 136, 14-15. | 1.4 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 37 | Specialty Pharmacy and Physician Partnership Optimizes Clinical Pathway Adherence in Myelofibrosis (MF): Initial Analysis of a Quality Improvement Initiative. <i>Blood</i> , 2020, 136, 40-41. | 1.4 | 0 |
| 38 | Impact of Letermovir Prophylaxis on Voriconazole Exposure in Allogeneic Hematopoietic Cell Transplant Recipients. <i>Blood</i> , 2020, 136, 5-6. | 1.4 | 0 |
| 39 | Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens. <i>Blood</i> , 2020, 136, 21-22. | 1.4 | 0 |
| 40 | Haploidentical Allogeneic Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide in Patients with Myelofibrosis: A Multi-Institutional Experience. <i>Blood</i> , 2020, 136, 33-34. | 1.4 | 4 |
| 41 | Symptom Burden and Blood Counts in Patients With Polycythemia Vera in the United States: An Analysis From the REVEAL Study. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, 579-584.e1. | 0.4 | 16 |
| 42 | Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia. <i>Blood Advances</i> , 2019, 3, 1939-1949. | 5.2 | 63 |
| 43 | Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia. <i>Blood Advances</i> , 2019, 3, 3052-3061. | 5.2 | 15 |
| 44 | The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia. <i>Blood Advances</i> , 2019, 3, 670-680. | 5.2 | 71 |
| 45 | Higher Incidence of Hemorrhagic Cystitis Following Haploidentical Related Donor Transplantation Compared with Matched Related Donor Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 785-790. | 2.0 | 38 |
| 46 | Effect of CYP3A4, CYP3A5, and ABCB1 Polymorphisms on Intravenous Tacrolimus Exposure and Adverse Events in Adult Allogeneic Stem Cell Transplant Patients. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 656-663. | 2.0 | 20 |
| 47 | Risk of Hemorrhage in Patients with Polycythemia Vera Exposed to Aspirin in Combination with Anticoagulants: Results of a Prospective, Multicenter, Observational Cohort Study (REVEAL). <i>Blood</i> , 2019, 134, 168-168. | 1.4 | 5 |
| 48 | Phase 1 Dose Escalation and Expansion Study to Determine Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the BET Inhibitor FT-1101 As a Single Agent in Patients with Relapsed or Refractory Hematologic Malignancies. <i>Blood</i> , 2019, 134, 3907-3907. | 1.4 | 17 |
| 49 | Allogeneic Transplantation for Myelodysplastic Syndrome in Adults over 50 Years Old Using Reduced Intensity/Non-Myeloablative Conditioning: Haploidentical Relative Versus Matched Unrelated Donor. <i>Blood</i> , 2019, 134, 3323-3323. | 1.4 | 2 |
| 50 | Patient Reported Financial Toxicity in Myeloproliferative Neoplasms. <i>Blood</i> , 2019, 134, 2099-2099. | 1.4 | 4 |
| 51 | Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 581-586. | 2.0 | 5 |
| 52 | Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera in the United States. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 788-795.e2. | 0.4 | 19 |
| 53 | Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, 590-596. | 0.4 | 22 |
| 54 | Patient Reported Financial Toxicity in Acute Leukemia. <i>Blood</i> , 2018, 132, 4796-4796. | 1.4 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|-----------|
| 55 | Microgranular acute promyelocytic leukemia presenting with leukopenia and an unusual immunophenotype. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2017, 10, 35-38. | 0.9 | 7 |
| 56 | Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 767-775. | 2.0 | 41 |
| 57 | A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. <i>Blood</i> , 2017, 129, 1143-1154. | 1.4 | 125 |
| 58 | Recent advances in hematopoietic cell transplantation in myelodysplastic syndrome. <i>Discovery Medicine</i> , 2017, 24, 51-57. | 0.5 | 0 |
| 59 | Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. <i>Journal of Clinical Oncology</i> , 2016, 34, 1864-1871. | 1.6 | 61 |
| 60 | Establishment of Subspecialized Care in Hematologic Malignancies and a Hematopoietic Cell Transplantation Program. <i>Blood</i> , 2016, 128, 3580-3580. | 1.4 | 0 |
| 61 | FLT3 Tyrosine Kinase Inhibition as a Paradigm for Targeted Drug Development in Acute Myeloid Leukemia. <i>Seminars in Hematology</i> , 2015, 52, 193-199. | 3.4 | 37 |
| 62 | Improved FLT3 Internal Tandem Duplication PCR Assay Predicts Outcome after Allogeneic Transplant for Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1989-1995. | 2.0 | 31 |
| 63 | Allogeneic Hematopoietic Cell Transplantation in Septuagenarians. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 1276-1278. | 2.0 | 0 |
| 64 | FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance. <i>International Journal of Hematology</i> , 2013, 97, 683-694. | 1.6 | 142 |
| 65 | Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation. <i>Blood</i> , 2013, 121, 4655-4662. | 1.4 | 355 |
| 66 | Are FLT3 inhibitors likely to improve FLT3-mutated acute myeloid leukemia in the foreseeable future?. <i>International Journal of Hematologic Oncology</i> , 2013, 2, 9-11. | 1.6 | 1 |
| 67 | Tandem Duplication PCR (TD-PCR) Is a Novel Method of Detecting Minimal Residual Disease in FLT3/ITD AML and Is Highly Predictive of Relapse Risk Following Allogeneic Transplant.. <i>Blood</i> , 2012, 120, 2479-2479. | 1.4 | 2 |